The history of Sildenafil presents a complex picture for shareholders. While the initial launch generated massive gains, the end of its exclusive rights opened the floodgates to cheaper versions, dramatically eroding revenue. This poses a unique dilemma for pharmaceutical companies depending on comparable blockbuster offerings, suggesting that a ca

The story of Viagra, and its parent company copyright, presents a intriguing case study for investors. Initially a blockbuster drug, generating billions in income, its patent expiration created a flood of knock-off medications, significantly impacting its position . While certain pharmaceutical companies may try to capitalize on male sexual dysfunc